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Abstract
Purpose – This paper aims to investigate the in vivo hypocholesterolemic property of fenugreek proteins
(FP), Purafect-fenugreek protein hydrolysate (PFPH) and Esperase-fenugreek protein hydrolysate (EFPH) on
high cholesterol (HC)-fed rats.
Design/methodology/approach – Rats were randomized into five groups: four were fed for four weeks
a hypercholesterolemic diet and the tested products were given by gavage. The fifth group was taken as
control (C) receiving the same diet without cholesterol.
Findings – Results showed that the elevated aspartate aminotransferase activity in HC group plasma was
significantly corrected by FP and EFPH administration (33 per cent; p = 0.0003). HC liver lipids and total
cholesterol (TC) contents were not markedly affected by FP and EFPH. However, liver triglycerides (TG)
contents trended to decrease in FP rats vs HC ( p = 0.07), while, the TG decrease was significant in groups fed
the proteins hydrolysates ( p = 0.02). On the other hand, serum TC and TG decreased by 53 per cent ( p =
0.0003) and 20 per cent ( p = 0.04), respectively, in FP treated rats compared to HC group. This decrease was
associated with a high fecal cholesterol excretion (2.5-fold higher in FP vs HC; p = 0.0001). Likewise, EFPH-
treated rats exhibited lower TC compared to HC rats ( p = 0.004). The very low density lipoprotins was the
main affected fraction in these two groups, while there were no significant difference in apolipoproteins (Apo)
B, A-I and A-IV contents between the different groups, except in FP group, where Apo A-I and A-IV
decreased by 26 and 17 per cent, respectively, compared to C rats ( p = 0.02). The high density lipoproteins
(HDL) of rats treated with proteins hydrolysates showed a better antioxidant property compared to those of
HC rats, which was accompanied with an increase in paraoxonase activity when compared to HC group.
Originality/value – Unlike PFPH which had almost no effect, FPs and EFPH could constitute a
nutraceutical ingredient in cardiovascular disease management.
Keywords Fenugreek, Hypercholesterolemia, HDL antioxidants properties, Lipoproteins,
Protein hydrolysates
Paper type Research paper
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1. Introduction
Hypercholesterolemia and oxidative stress is one of the leading causes of atherosclerosis
and cardiovascular diseases (CVD). These two factors are often observed in the modern life
style. As consequence of the world life transition, CVD, and especially dyslipidemia, had
immensely increased either in occidental societies or in emerging countries, reaching a
prevalence of 53 per cent in the USA, 50.5 per cent in Spain and 48 per cent in France (with
30 per cent for hypercholesterolemia) (Ferrières et al., 2009; Guallar-Castillon et al., 2012;
Toth et al., 2012). In Algeria, the prevalence of dyslipidemia is less than 15 per cent as
reported in “Epidemiological Transition and Health Impact in North Africa (TAHINA)
Survey 2002” (Institut National de Santé Publique, 2007).
It is generally established that the nutritive and non-nutritive constituents of food can be
used to prevent the risk of developing or complicating human disease conditions (Bouchenak
and Lamri-Senhadji, 2013). Fenugreek (Trigonella foenum-graecum) is a leguminous used as
food and spice for seasoning (Srinivasan, 2013). It is equally used in Indian and Chinese
traditional medicine for the treatment of many diseases (Bukhari et al., 2008), as well as in the
Mediterranean countries, Western countries, Asia and Africa. The seeds are the most
important and useful part of this plant (Meghwal and Goswami, 2012). Many of the
functional and medicinal properties of fenugreek are attributed to its chemical composition
(20-25 per cent protein, 45-50 per cent dietary fiber, 20-25 per cent mucilaginous soluble fiber,
6-8 per cent fatty acids and essential oils and 2-5 per cent steroidal saponins) (Khorshidian
et al., 2016). Most of these constituents have been investigated in recent studies (Mowla et al.,
2009; Madhava Naidu et al., 2011; Reddy and Srinivasan, 2011; Elmnan et al., 2012; Belguith-
Hadriche et al., 2013; Habib-Martin et al., 2017). To the best of our knowledge, although these
studies clearly demonstrated the beneficial role of non-protein components such as saponine,
fiber, flavonoid and trigoneline on lipid metabolism and redox status (El Khoury and
Anderson, 2013), no comparative study has been conducted on the role of fenugreek proteins
(FP) or their hydrolysates on hypercholesterolemia. Indeed, fenugreek is a rich protein
legume and because of its high protein content and its favorable amino acid composition, the
seeds could be a potential source of bioactive peptides (Christiane et al., 2009).
Indeed, in addition to their nutritional function, proteins can also be considered as
bioactive molecules providing other functional and nutraceutical properties (Garcia et al.,
2013; Lopez-Barrios et al., 2014). In this regard, administration of proteins from different
sources have shown promising results in improving the quality of life, particularly in CVD
and dyslipidemia prevention (Möller et al., 2008; Ruiz et al., 2014; Udenigwe and Rouvinen-
Watt, 2015). In fact, the action of proteins is because of their nature and their amino acid
composition. In addition, more recent studies have shown that the proteins may also contain
biologically active peptide sequences which, after their release during gastrointestinal
digestion, are responsible in part of their properties. Moreover, it is believed that some of
these peptides exhibit the same properties of the protein that contained them but with
greater potential or even exhibit new properties. According to researchers, the release of
these bioactive peptides from their proteins is also possible by controlled hydrolysis in vitro
(Sarmadi and Ismail, 2010; Lemes et al., 2016; Cicero et al., 2017; Nasri, 2017).
Themain biological cardioprotective activities attributed to bioactive peptides to date are
antioxidant, hypolipidemic, antithrombotic and antihypertensive (Sarmadi and Ismail, 2010;
Cicero et al., 2017). The exact mechanism by which proteins decreased cholesterolemia is not
fully understood. In this sense, it has been reported that protein hydrolysates and peptides
exhibited hypocholesterolemic activity via bile acid binding and disruption of cholesterol
micelles in the gastrointestinal tract, and/or by altering hepatic and adipocytic enzymes
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activities and gene expression of lipogenic proteins, which can modulate aberrant
physiological lipid profiles (Udenigwe and Howard, 2013).
In the present study, the hypocholesterolemic and antioxidant properties of FG proteins
and their hydrolysates obtained by using two commercial enzymes (Purafect or Esperase)
were investigated in rats that were fed hypercholesterolemic diet. Fenugreek was chosen for
its high proteins content and its favorable amino acid composition.
2. Material and methods
2.1 Preparation of fenugreek proteins
Fenugreek was purchased from a local spices market in the city of Tiaret (Algeria). Seeds
were then cleaned, grounded to a fine powder and defatted in Soxhlet (Labotech LT-6,
Rosdorf, Germany) by using n-hexane for 12 cycles (10 h) and the FP were purified
according to Boye et al. (2010) method. The defatted powder was solubilized with distilled
water in a ratio of 1:20 (w/v) and the pH was adjusted to 10 with 1N NaOH solution. After
30 min, the preparation was centrifuged (Refrigerated Centrifuge Sigma DE) at 2,000 g for
30 min at 4°C and the resulting supernatant was brought to isoelectric point (pH 4.5) with 2N
HCl. Proteins were removed after centrifugation (3,000 g for 30 min) and rinsed twice with
distilled water. The purified proteins isolate was freeze dried and stored at 4°C. The nitrogen
content in FP isolate was determined according to the AOAC method number 984.13
(Horwitz, 2000), and crude protein, estimated by multiplying total nitrogen content by the
factor of 6.25. FP isolate contained 80.3 per cent of total proteins.
2.2 Preparation of fenugreek protein hydrolysates
FPs were hydrolyzed by using Esperase® (pH 9.0; 50°C) or Purafect® 2000E (pH 10.0; 50°C)
both from Sigma Chemical Co. (St. Louis, MO, USA). FPs isolate was dissolved in distilled
water at a proportion of 5 per cent (w/v). The pH and temperature were then adjusted to
optimum enzyme activity prior to their addition. The enzyme/protein ratio was fixed at 5
(U/mg of protein). Once the enzyme was added, the pH of the solution was maintained
constant by a continuous addition of 2N NaOH solution. The degree of hydrolysis of FP was
monitored using a pH-stat method (Adler-Nissen, 1986).
DH %ð Þ ¼ h
htot
 100 ¼ B NB
MP
 1
a
 1
htot
 100
where B is the amount (mL) of NaOH consumed to keep the pH constant during the reaction,
NB is the normality of NaOH, MP is the mass of proteins (g) and a is the average degree of
dissociation of the a-NH2 groups released during hydrolysis. The total number of peptide
bonds (htot) was assumed to be 7.6 meq/g.
When the degree of hydrolysis reached its maximum value, the reaction was stopped by
heating the solution at 90°C for 10 min, and the digest was cooled at room temperature and
then centrifuged at 5,000 g for 15 min. The supernatant fraction containing FP hydrolysates
was collected, freeze dried (104 h for a volume of 500 mL) then stored at 4°C until use. The
respective final degrees of hydrolysis of the obtained hydrolysates were 19 and 9 per cent for
Esperase-fenugreek proteins hydrolysate (EFPH) and Purafect-fenugreek proteins
hydrolysate (PFPH). Protein contents of PFPH and EFPH were estimated at 90 and 92.5 per
cent, respectively, and their amino acids composition was determined (Table I) according to
Soufleros and Bertrand (1998).
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2.3 Animal treatment
In total, 30 male Wistar rats, weighing about 184 6 7 g, purchased from Algiers Pasteur
Institute (Algeria), were housed in cages in a room maintained at 22°C and 60 per cent
relative humidity with a 12-h cycle of light and dark. Rats were given free access to tap
water and food throughout the experiment. Animals were kept according to the general
guidelines on the use of living animals in scientific investigation (Council of European
Communities, 1986), and the institutional committee on animal care and use approved the
protocol and use of rats (approval number DZ-TN371/13).
2.4 Experimental design
In all, 24 rats were fed during four weeks a hypercholesterolemic (HC) diet (Table II)
containing 20 per cent casein supplemented with 1 per cent cholesterol and 0.5 per cent
cholic acid and randomized into four groups of six rats each as follow:
 HC group receiving daily 1 g/kg body weight (BW) of casein.
 FP group daily receiving 1 g/kg BW of FPs.
 PFPH group daily receiving 1 g/kg BW of PFPH.
 EFPH group daily receiving 1 g/kg BW of EFPH.
A fifth group (control: C) was fed the same experimental diet without cholesterol/cholic acid
and treated under the same conditions with 1 g of casein/kg BWgiven by gavage.
Animals were weighed twice a week, and food consumption was recorded daily. In the
last week of the experiment, rats of each group were kept for three days in metabolic cages
and feces were daily collected, then dried, weighed and stored at 40°C until analysis. At
the end of the experiment, the overnight fasting rats were anesthetized with sodium
Table I.
Amino acids
composition of FPs
and their
hydrolysates
(%) FP EFPH PFPH
Cys 0.76 0.1 0.96 0.0 0.86 0.1
Met 0.86 0.1 1.06 0.0 1.06 0.0
Asp/Asn 11.46 0.1 12.66 0.3 11.26 0.0
Thr 3.66 0.1 3.96 0.1 4.76 0.0
Ser 5.06 0.1 3.96 0.1 3.96 0.1
Glu/Gln 12.76 0.3 14.36 0.2 14.06 0.0
Pro 3.96 0.1 3.26 0.2 3.56 0.0
Gly 3.56 0.2 3.56 0.1 3.86 0.1
Ala 5.96 0.1 5.96 0.2 5.86 0.1
Val 6.16 0.1 5.06 0.1 5.26 0.1
Ile 6.56 0.2 6.06 0.0 5.76 0.2
Leu 9.66 0.1 10.06 0.2 11.16 0.1
Tyr 2.76 0.3 2.96 0.2 3.16 0.0
Phe 3.56 0.1 3.26 0.0 3.46 0.0
Lys 5.66 0.3 5.86 0.0 5.76 0.2
His 3.16 0.2 2.76 0.1 2.56 0.1
Trp 11.66 0.2 11.16 0.1 10.36 0.0
Arg 4.26 0.1 4.06 0.2 3.96 0.1
Notes: Amino acid composition was determined by HPLC (Soufleros and Bertrand, 1998). All
measurements were performed in triplicate at the Regional Laboratory Quality Control and the Repression
of fraud of Oran. Data are presented as mean6 SD
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pentobarbital (60 mg/kg). Blood samples were collected from the abdominal aorta and serum
was obtained by low speed centrifugation (2000 g, 30 min at 4°C). Liver was excised, washed
in ice-cold saline (150 mMNaCl) and stored at40°C until analysis.
2.5 Biochemical analysis
Glycaemia was measured by using glucose oxydase kit and uric acid by uricase-peroxidase kit
(Spinreact, Girona, Spain). Serum protein and albumin concentrations were measured by the
methods of Biuret (Chronolab Kit, Barcelona, Spain) and Bromocresol Green (Biolabo kit, Maizy,
France), respectively. Alanine aminotransferase (ALAT) and aspartate aminotransferase
(ASAT) activities were assayed using commercial kits (Spinreact, Girona, Spain).
Serum thiols were determined by a colorimetric assay as described by Sedlak and
Lindsay (1968) using Ellman reagent. The results were calculated using the molar
absorption coefficient of TNB « = 14.15 103 M1.cm1 (Eyer et al., 2003).
2.6 Hepatic and fecal lipid extraction
One gram of liver or feces was extracted with chloroform:methanol (2:1, v/v) according to the
method of Folch et al. (1957). After solvent evaporation, lipids extract was dissolved in
isopropyl alcohol and immediately analyzed.
2.7 Lipids analysis
Serum and liver triacylglycerol (TG) and total cholesterol (TC), unesterified cholesterol (UC)
and phospholipids (PL) concentrations were measured by using commercial kits (Spinreact,
Girona, Spain), (Biolabo, Maizy, France) and (Cypress, Langdorp, Belgium), respectively.
Esterified cholesterol (EC) levels were deduced from the difference between TC and UC.
2.8 Lipoproteins fractionation and lipid sand apolipoproteins analysis
Fast protein liquid chromatography in Äkta-FPLC (Amersham Pharmacia Biotech,
Barcelona, Spain) was used for analysis of the lipoproteins profile using 50 mM phosphate
buffer sodium (PBS) as running buffer following the method described by Hubácek et al.
(2008). A volume of 150 mL of each serum pool was loaded on a SuperoseTM 6 10/300 GL
column (GE healthcare life sciences, Barcelona, Spain) and 0.5 mL of each fraction was
Table II.
Composition of
cholesterol-enriched
diet (g/kg diet)a
Ingredients C HC
Caseinb 200 200
Corn starchc 597 582
Sucrosed 40 40
Sunflower oile 50 50
Cellulose powderf 50 50
Mineral mixg 20 20
Vitamin mixh 40 40
Cholesterolb 0 10
Cholic acidb 0 5
Methioninei 3 3
Notes: aThe diet contained 16 MJ/kg and was given in powdered form. bSigma-Aldrich Chemie, Germany.
cMaghnia Starch, Tlemcen, Algeria. dCommercial sugar, Cevital, Bejaia, Algeria. eCommercial oil (80% soy
oil and 20% sunflower oil), Cevital, Bejaia, Algeria. fAgar, Liofilchem, Italie. gMx SAFE 205B, Augy,
France. hVit SAFE 200, Augy, France. iBiochem Chemopharma, Canada
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collected. The elution was monitored at 280 nm for proteins content and collected in
fractions.
The TC in each fraction was measured by a fluorometric method using Amplex Red
(Molecular Probes, OR, USA). The phosphatidylcholine (PC) was determined by using the
enzymatic procedure (Hojjati and Jiang, 2006) coupled to fluorometric detection (He et al.,
2002). Serum apolipoproteins (apo B, A-I and A-IV) were quantified by ELISA using specific
polyclonal antibodies (Navarro et al., 2005).
2.9 Lipoproteins oxidation susceptibility and high density lipoproteins antioxidant potential
The susceptibility of very low density lipoproteins and low density lipoproteins cholesterol
(VLDL-LDL-c) to oxidation and the antioxidant potential of high density lipoproteins (HDL)
to prevent low and very low density lipoproteins against oxidation in rats was measured
according to the fluorometric method of Navab et al. (2001), as modified by Acín et al. (2006),
using dichlorofluorescein (DCF) (Sigma, MO, USA) as an oxidation marker.
Two volumes of a preparation containing 100 mg/mL of VLDL-LDL-cholesterol and
4 mg/mL of HDL-cholesterol were mixed with 1/2 volume of 0.12 per cent sodium azide and
1/2 volume of DCF (80 mg/mL). After incubation for 3 h at 37°C, the intensity of the
fluorescence of the DCF is measured. A control (for VLDL-LDL-c oxidation susceptibility)
was prepared for each group by following the same steps with substituting HDL by PBS.
The samples were analyzed in duplicate. The antioxidant index (AOI) of HDL is expressed
as the percentage of non-HDL oxidation inhibition.
2.10 Paraoxonase activity assay
Paraoxonase activity (PON1) was determined in serum by measuring the conversion rate of
phenyl acetate to phenol as described by Eckerson et al. (1983). In total, 5 mL of
appropriately diluted serum was added to 200 mL of working reagent (20 mM Tris/HCl
buffer, pH 8.0, containing 1 mM CaCl2 and 4 mM phenyl acetate). The increase of the
absorbance was recorded at 270 nm (25°C) every 30 s. One unit of arylesterase activity is
equal to one mMof phenol formed per minute. The activity was expressed in U/mL based on
the extinction coefficient of phenol (1,310 M1cm1). Blank sample containing buffer was
used to correct for non-enzymatic hydrolysis.
2.11 Statistical analysis
Data are presented as mean 6SD and subjected to one way ANOVA and LSD-Fisher post
hoc test. Differences are considered to be significant at p # 0.05 and were superscripted by
(*) between HC rats and C group and by (#) between treated groups and HC one.
3. Results and discussion
3.1 Food intake, body weight and liver relative weight
The first objective of our study was to determine whether FP and their hydrolysates affect
the dietary nutritional properties and hepatic function. Under our experimental conditions,
neither food intake nor body weight changes were observed after the administration of FP,
PFPH or EFPH, suggesting that FPs and their two hydrolysates, did not affect the
nutritional efficiency of the given diet, permitting therefore a normal body weight growth.
These results confirmed those previously published by Yahia et al. (2017) using chickpea
protein hydrolysates. Similarly, Bettzieche et al. (2008) did not find any significant difference
in body weight, after 20 days, between high cholesterol (HC)-fed rats receiving, daily, 1g of
lupin or casein proteins, and those fed a control diet. Likewise, Yang et al. (2007) reported
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that the treatment with soy proteins and their hydrolysate (1g/day for 12 weeks) did not
change body weight and food intake of rats.
However, when analysing liver relative weight, values were significantly increased by
1.3-fold in the four groups fed the hypercholesterolemic diet when compared to C group
(Table III). This result could be explained by the high fat storage in liver of treated rats.
Indeed, the higher lipid contents found in this organ indicated that FPs and their
hydrolysates did not prevent liver lipid storage induced by the hypercholesterolemic diet.
3.2 Serum alanine aminotransferase and aspartate aminotransferase activities
In the present study, the hypercholesterolemic diet induced a slight increase of serum ASAT
activity while ALAT activity was unchanged between the five groups. It has been
previously reported by Ktari et al. (2015), that the hepatocytes were particularly vulnerable
to lipid accumulation, which can cause deterioration of membrane integrity resulting in the
release of several components, including transaminases, from their cytosol. The observed
result suggested that liver damage was not advanced in HC rats (Kapravelou et al., 2013)
and could explain the unchanged ALAT activity in HC group. However, ASAT activity of
the groups treated with FP and EPFH was 1.3-fold lower than value obtained with the HC
group ( p = 0.0003) and became comparable to that of C group (Table III). This indicated
that FP and EFPH protected liver against the deleterious effect of HC diet. These results
were consistent with those of Kapravelou et al. (2013) who also observed that lupin protein
hydrolysate attenuated hepatoxicity in high cholesterol-diet-fed rats.
3.3 Liver lipid contents
As depicted in Table IV, and compared to C group, all the liver lipids components were
significantly higher in all HC-fed groups (HC, FP, PFPH and EFPH). The high contents of
lipids, cholesterol and triglycerides in liver observed in HC non-treated animals vs C were
probably a consequence of two mechanisms. Effectively, it has been estimated that, in rats,
as much as 50 per cent of dietary fat enters the liver as remnant TG (Babin and Gibbons,
2009). The second mechanism is the stimulation of acyl-CoA cholesterol acyl transferase
expression in liver by HC diet as mentioned by Wang et al. (2010). When compared to HC
group, TC concentrations were reduced by 24 per cent in PFPH rats’ liver ( p = 0.03). UC
levels in FP rats were increased by 27 per cent vs HC group ( p= 0.07).
Table III.
Anthropometric
parameters and
serum transaminases
activities of rats
treated or not with
FPs and their
hydrolysates
Groups C HC FP PFPH EFPH
Initial BW (g) 1856 04 1846 09 1846 02 1836 04 1896 11
Final BW (g) 2366 18 2406 26 2336 13 2496 21 2516 30
Food intake (g/d) 176 2 196 4 226 5 196 5 206 3
Food efficiency ratio (%) 0.13 0.126 0.05 0.086 0.01 0.126 0.01 0.116 0.03
Liver relative weight (%) 2.86 0.1 3.76 0.2* 3.86 0.2* 3.76 0.3* 3.86 0.2*
ASAT (U/l) 586 9 706 7 476 6# 726 11 476 7#
ALAT (U/l) 206 3 236 5 276 7 266 7 296 8
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; BW: body
weight; ASAT: aspartate aminotransferase; ALAT: alanine aminotransferase; data are presented as mean
of 6 rats per groups. Superscripted (#, *) means within a row indicate they are significantly different at P <
0.05, as following: *HC, FP, PFPH or EFPH vs C. #FP, PFPH or EFPH vs HC
Antioxidant
properties in
rats
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
Liver triacylglycerol contents decreased (1.3-fold lower), but not significantly
( p = 0.07), in rats fed FP. In PFPH and EFPH groups, these contents were significantly
lower (30 per cent, p = 0.02), both compared to HC. Furthermore, PL values did not
show any significant difference between HC, FP, PFPH and EFPH rat groups. These
results were in agreement with the works of Fassini et al. (2011) and Yang et al. (2007)
who did not notice significant changes in liver cholesterol contents between HC and soy
protein or its hydrolysate treated rats. In contrast, this work results were not wholly in
line neither with the studies of Ferreira et al. (2015) and Kapravelou et al. (2013) who
noticed a diminution of cholesterol and TG levels after protein or hydrolysate
supplementation, nor with those of Bettzieche et al. (2008) who remarked that lupin
protein had diminished only TG concentrations in liver vs HC group.
3.4 Glycaemia, serum lipids contents and fecal cholesterol excretion
Although glycaemia of all the experimental groups was normal, results showed a slight
increase of blood glucose level in HC group compared with C group ( p = 0.02). This was
corrected after treatment with FP ( p = 0.04 vs HC), suggesting a possible regulating effect of
glycaemia by FP consumption.
The ability of FPs and their hydrolysates to prevent hypercholesterolemia complications
in HC-diet-fed rat was further examined. After 28 days, and compared to control diet, HC
diet induced a sharp increase of cholesterolemia by 439 per cent mainly in VLDL fraction.
The TC increase, similarly observed in early works (Athmani et al., 2015; Benomar et al.,
2015; Yahia et al., 2017), was concomitant with hypertriglyceridemia state (1.6-fold higher)
(Table V). These findings were in contrast with those reported by Leon-Espinosa et al. (2016)
andWang et al. (2010) showing that the HC diet decreased serumTG levels.
Compared to HC group, FP ( p = 0.0003) and their hydrolysate produced by Esperase
( p = 0.004) caused a significant decrease in serum TC (53 and34 per cent, respectively).
The decreased cholesterolemia in FP group resulted from the low levels of the unesterified
and esterified pools that were, respectively, reduced by 35 and 60 per cent, while, regarding
EFPH group, only the esterified pool was decreased by 38 per cent, all compared with HC
animals. The main hypothesis advanced to explain the observed cholesterol-lowering effect
Table IV.
Liver lipids contents
in rats treated or not
with FPs and their
hydrolysates
Groups C HC FP PFPH EFPH
mg/g liver
Total lipids 716 6 1936 21* 2256 18* 184633* 198625*
mmol/g liver
TC 9.56 0.7 67.06 10.6* 75.06 10.0* 50.966.7*# 76.269.3*
UC 2.76 1.8 7.16 1.7* 9.056 1.9*# 7.36 1.0* 5.86 0.9*
CE 6.86 1.3 59.96 9.4* 64.46 4.7* 43.66 7.0*# 70.36 10.7*
TG 6.56 1.1 20.06 2.8* 15.76 5.0* 14.16 2.1*# 14.76 2.9*#
PL 34.06 5.5 52.56 6.2* 47.46 8.3 64.56 15.3* 51.86 4.9*
CE/UC 2.51 8.43 7.11 5.97 12.12
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; TC: total
cholesterol; UC: unesterified cholesterol; CE: cholesteryl ester; TG: triglycerides; PL: phospholipids; data are
presented as mean 6 SD of 6 rats per groups. Superscripted (#, *) means within a row indicate they are
significantly different at P< 0.05, as following: *: HC, FP, PFPH or EFPH vs C. #FP, PFPH or EFPH vs HC
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is the inhibition of cholesterol and lipids absorption (Ferreira et al., 2015; Yahia et al., 2017)
as shown by the high fecal cholesterol excretion in FP-treated group (P = 0.0001). However,
EFPH treated rats did not show any difference in fecal cholesterol compared with HC rats. In
fact, Cho et al. (2007) reported that the in vitro effect of soy proteins on cholesterol micellar
solubility was reduced after the hydrolysis of the intact proteins. It is possible that EFPH,
via its small peptides fractions, passed the intestinal barrier and reached the systemic blood
stream, then liver, where they could exert their bioactivities. This could also explain why
EFPH (degree of hydrolysis =19 per cent), and not PFPH (degree of hydrolysis = 8 per cent),
affected serum cholesterol concentration. Indeed, PFPH-treated rats exhibited 1.2-fold higher
TC vs HC.
FP supply-induced serum TG decreased by 20 per cent when compared to HC group ( p =
0.04). Moreover, the lowest PL levels were found with FP diet, unlike the others groups,
where values were similar (Table V).
3.5 Cholesterol and phosphatidylcholine distribution on lipoproteins fractions
The effect of FP and their hydrolysates for the possible changes of cholesterol and PC
distribution in different lipoproteins fractions was also assessed. With control diet, the
obtained FPLC lipoproteins profile revealed that the highest cholesterol contents were found
in HDL followed by VLDL. Nevertheless, this profile was changed by the HC diet as
indicated by the highest amounts of VLDL followed by HDL (Figure 1). HDL-cholesterol
(HDL-c) contents were markedly decreased in HC, FP and EFPH groups compared to C.
However, compared with HC, FP and EFPH reduced VLDL-cholesterol (VLDL-c) and-
phosphatidylcholine (VLDL-PC), while PFPH did not show any effect. Furthermore, in rats
treated with PFPH, a redistribution of cholesterol toward HDL and cholesterol poor-HDL
fractions was observed.
PC distribution in lipoproteins fractions of C and HC groups showed that PC was mainly
observed in VLDL followed by HDL, smaller HDL and LDL. Compared to HC group, FP and
EFPH induced a decrease in the phospholipid content of all lipoprotein fractions whereas
PFPH exhibited the highest PC accumulation in the smaller HDL.
Table V.
Glycaemia, serum
lipids contents and
fecal cholesterol
excretion in treated
or not with FPs and
their hydrolysates
Groups C HC FP PFPH EFPH
mmol/l
Glycaemia 3.266 0.22 4.996 0.60* 3.756 0.49# 4.876 0.64* 3.786 0.75
TC 1.436 0.04 6.296 1.14* 2.956 0.46# 7.806 1.79* 4.126 0.76*#
UC 0.726 0.01 1.626 0.53* 1.066 0.04# 1.586 0.43* 1.236 0.30*
CE 0.716 0.05 4.676 1.00* 1.886 0.45# 6.216 1.54*# 2.896 1.04*#
TG 0.666 0.30 1.096 0.09* 0.876 0.16# 1.146 0.19 1.036 0.06
PL 1.986 0.42 2.276 0.46 1.616 0.10# 2.616 0.54 1.866 0.32
mg/day/rat
Fecal cholesterol 1.86 0.3 19.36 5.8* 50.66 6.9*# 17.66 1.5* 21.66 8.3*
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; TC: total
cholesterol; UC: unesterified cholesterol; CE: cholesteryl ester; TG: triglycerides; PL: phospholipids; data are
presented as mean 6 SD of 6 rats per groups. Superscripted (#, *) means within a row indicate they are
significantly different at P< 0.05, as following: *:HC, FP, PFPH or EFPH vs C. #FP, PFPH or EFPH vs HC
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Similar results have been obtained by Ferreira et al. (2015) and Yang et al. (2007), showing
that legume proteins and their hydrolysates decreased the non HDL-c amounts; however,
they noticed an increase in HDL-c levels. The decreased HDL-c contents in all rats given the
HC diet suggest that the reverse cholesterol transport was up regulated.
3.6 Serum apolipoproteins A-I and A-IV
Regarding C, HC, PFPH and EFPH groups, serum apolipoproteins B, A-I and A-IV were
similar (Table VI). The HC and PL contents in VLDL, and the unchanged Apo B100, which
reflect the number of VLDL and LDL particles, suggest that HC diet altered the composition
of the VLDL core lipids rather than their synthesis or uptake by liver. Furthermore, Kang
and Davis (2000) reported that when the amount of cholesterol increased in liver, the
composition of the VLDL core lipids changed (i.e. increase the relative amount of cholesterol
Figure 1.
Cholesterol (TC) and
phosphatidylcholine
(PC) distribution in
serum rats
lipoproteins treated
or not with FPs and
their hydrolysates
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Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek
protein group; PFPH: Purafect-fenugreek proteins hydrolysate group,
EFPH: Esperase-fenugreek proteins hydrolysate group; Serum lipoproteins
were separated by FPLC and collected fractions analyzed for total
cholesterol (TC), phosphatidylcholine (PC). Data are presented as
representative profile of six pooled animals serum
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esters to triglycerides) while the number of VLDL particles, assembled and secreted by this
organ, remains the same.
However, FP decreased Apo A-I ( p = 0.03) and A-IV ( p = 0.02) levels compared with C
rats. In a recent work of Yahia et al. (2017), who studied the hypercholesterolemic effect of
chickpea proteins hydrolysate on rats, no change in Apo A-I of HDL was founded, while an
increase in Apo A-IV contents was noticed in this particle. Two possible mechanisms could
explain the decrease of Apo A-I in FP group. The first one is the increase of its uptake by
liver, and the second one consists on the decrease of its synthesis (Röhrl and Stangl, 2013). It
is the first hypothesis rather than the second that could be advanced in the present study.
Indeed, Apo A-I profile in FP rats serum showed a lower Apo A-I contents in their largest
lipoproteins but not in the smallest ones. Further investigations should be undertaken to
well understand the FP effect on HDLmetabolism.
Apo A-IV is synthesized primarily by intestine and liver (Duka et al., 2013). Therefore,
the post-absorptive Apo A-IV level reflected indirectly its post-prandial metabolism. The
lower Apo A-IV levels observed in FP serum rats vs C could be because of the reduced
enterocyte lipid absorption by FP treatment which involved a down-regulation of Apo A-IV
gene synthesis and then impaired its redistribution toward HDL (Duka et al., 2013).
3.7 Proteins and oxidant stress markers
Compared with control diet, HC diet increased serum proteins. Nonetheless, after treatment
with FP, PFPH or EFPH, the serum protein levels decreased (15, 17 and 27 per cent,
respectively compared to HC) and became similar to that of C group. Serum albumin did not
show any significant difference among all groups (Table VII). However, and compared to
animals fed control diet, serum uric acid markedly increased by HC feeding. This increase
Table VII.
Proteins and oxidant
stress markers in rats
treated or not with
FPs and their
hydrolysates
Groups C HC FP PFPH EFPH
Proteins (g/l) 626 15 736 6 626 1# 606 4# 536 6#
Albumin (g/l) 266 4 286 3 286 3 276 4 246 3
Uric acid (mM) 1256 9 1536 8* 1596 10* 1716 16*# 1586 14*
Thiols (mM) 0.196 0.07 0.496 0.26 0.326 0.13 0.446 0.17 0.376 0.12
Paraoxonase (U/ml) 1096 8 946 8 946 10 1166 6# 1126 8#
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; dara are
presented as mean 6 SD of 6 rats per groups. Superscripted (#, *) means within a row indicate they are
significantly different at P< 0.05, as following: * HC, FP, PFPH or EFPH vs C. #FP, PFPH or EFPH vs HC
Table VI.
Apolipoproteins B,
A-I and A-IV
contents in serums of
rats treated or not
with FPs and their
hydrolysates
Arbitary unit C HC FP PFPH EFPH
Apo B 0.246 0.04 0.246 0.04 0.216 0.01 0.246 0.04 0.226 0.03
Apo AI 0.646 0.01 0.596 0.06 0.536 0.05* 0.576 0.06 0.616 0.05
Apo AVI 0.756 0.04 0.696 0.11 0.566 0.06* 0.796 0.06 0.756 0.10
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; data are
presented as mean 6 SD of 6 rats per groups. Superscripted (*) means within a row indicate they are
significantly different at P< 0.05, as following: *: HC, FP, PFPH or EFPH vs C
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could probably be because of the higher xanthine oxidase activity mainly induced by the HC
diet responsible of the hepatic injury. Similar hypothesis was previously proposed by
Devrim et al. (2008). Indeed, uric acid is the end product of purine nucleotide catabolism by
xanthine oxidase. It seems that neither FP nor their hydrolysates could prevent the increase
of uric acid. In spite of the high thiol values observed in all treated groups, compared to C
group, these differences were not significant.
3.8 Antioxidative action of HDL
Several studies have shown that exogenous antioxidants, especially originated from foods,
are essential for counteracting oxidative stress (Shahidi et al., 1992). In our protocol design,
the potential of FPs and their hydrolysates to change oxidant/antioxidant status in
hypercholesterolemic rat was assessed.
Products of lipid peroxidation, especially fatty acyl residues within phospholipids,
present in oxidized-LDL can induce pro-inflammatory phenotypes in arterial wall cells,
which contribute to endothelial dysfunction and apoptotic cell death, as the key steps of
the initiation and progression of atherosclerosis lesions (Hafiane and Genest, 2013).
Whereas, besides its role of ensuring the reverse transport of cholesterol, HDL plays an
important function in protecting against non-HDL oxidation. This property is
attributed to some proteins and enzymes (Hafiane and Genest, 2013). To evaluate the
AOI of the treated rats HDL, non-HDL fraction of each group was incubated with and
without the HDL of the same group and the inhibitory property of their oxidation was
estimated.
In the absence of HDL, the highest VLDL-LDL oxidation level was observed in PFPH
followed by EFPH groups, while the lowest oxidation was obtained in the C group
(Table VIII). This could not be because of the amounts of lipids in these lipoproteins as, for
the same levels of cholesterol, PL contents were almost the same. However, this high
oxidability could be because of the nature of acyl groups in lipids. In FP group, the non-HDL
fraction was less susceptible to oxidation than that of HC.
On the other hand, the HDL of PFPH and EFPH groups showed a remarkable
antioxidative effect (59 and 43 per cent, respectively) compared to HC group (13 per
cent) ( p = 0.001). These results could be attributed to the elevated PON1 activity (20 and 15
per cent higher in PFPH and EFPH, respectively, compared to HC group; Table VII)
probably because of the direct effect of some peptides within hydrolysates or to an up-
regulation as response to the high oxidation of the non-HDL fraction. According to Aviram
et al. (1999), PON1 is inhibited in presence of oxidized LDL. However, this inhibition is
countred by antioxidants. Hence, it could be possible that the hydrolysates were implicated
in the increase of PON1 activity.
Table VIII.
AOI of HDL
separated from
serum of rats treated
or not with FPs and
their hydrolysates
Arbitary unit C HC FP PFPH EFPH
(VLDL-LDL) 92.66 0.0 166.06 15.3* 89.56 12.5# 257.86 25.4*# 170.86 34.7*
(VLDL-LDL)
þHDL
76.46 0.0 144.96 6.4* 95.86 12.2# 106.36 19.2*# 97.56 23.9*#
Notes: C: Control group; HC: hypercholesterolemic group; FP: fenugreek protein group; PFPH: Purafect-
fenugreek proteins hydrolysate group, EFPH: Esperase-fenugreek proteins hydrolysate group; data are
presented as mean 6 SD of 6 rats per groups. Superscripted (#, *) means within a row indicate they are
significantly different at P< 0.05, as following: *: HC, FP, PFPH or EFPH vs C. #FP, PFPH or EFPH vs HC
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4. Conclusion
FPs and EFPH exhibited an interesting hypocholesterolemic and hypotriglyceridemic
activity, accompanied with an antioxidant property. The synergetic use of FPs and their
Esperase hydrolysate could represent a promising nutraceutical ingredient in foods for the
prevention against hypercholesterolemia complications. However, with the lack of
information and investigations, it was not possible to settle if the hypocholesterolemic effect
of FPs and their Esperase hydrolysate was mediated by their direct action on cellular or
subcellular level or if it was just a consequence of the inhibition of cholesterol and lipid
absorption in gut. Further works may bring more elucidations to well understand the exact
mechanism bywhich they act.
References
Acín, S., Navarro, M.A., Arbonés-Mainar, J.M., Guillén, N., Sarría, A.J., Carnicer, R., Surra, J.C., Orman,
I., Segovia, J.C., De La Torre, R., Covas, M.I., Fernández-Bolaños, J., Ruiz-Gu, V. and Osada, J.
(2006), “Hydroxytyrosol administration enhances atherosclerotic lesion development in apo E
deficient mice”,The Journal of Biochemistry, Vol. 140 No. 3, pp. 383-391.
Adler-Nissen, J. (1986), “A review of food hydrolysis specific areas”, in Adler-Nissen, J. (Ed.), Enzymic
Hydrolysis of Food Proteins, Elsevier, Copenhagen, pp. 57-109.
Athmani, N., Dehiba, F., Allaoui, A., Barkia, A., Bougatef, A., Lamri-Senhadji, M.Y., Nasri, M. and
Boualga, A. (2015), “Sardina pilchardus and sardinella aurita protein hydrolysates reduce
cholesterolemia and oxidative stress in rat fed high cholesterol diet”, Journal of Experimental
and Integrative Medicine, Vol. 5 No. 1, pp. 47-54.
Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton, R.S. and La
Du, B. (1999), “Human serum paraoxonase (PON1) is inactivated by oxidized low density
lipoprotein and preserved by antioxidants”, Free Radical Biology and Medicine, Vol. 26
Nos 7/8, pp. 892-904.
Babin, P.J. and Gibbons, G.F. (2009), “The evolution of plasma cholesterol: direct utility or a ‘spandrel’
of hepatic lipid metabolism?”, Progress in Lipid Research, Vol. 48 No. 2, pp. 73-91.
Belguith-Hadriche, O., Bouaziz, M., Jamoussia, K., Simmonds, M., El Feki, A. and Makni-Ayedi, F.
(2013), “Comparative study on hypocholesterolemic and antioxidant activities of various
extracts of fenugreek seeds”, Food Chemistry, Vol. 138 Nos 2/3, pp. 1448-1453.
Benomar, S., Yahia, S., Dehiba, F., Guillen, N., Rodriguez-Yoldi, M.J., Osada, J. and Boualga, A. (2015),
“Differential antioxidative and hypocholesterolemic responses to two fish protein hydrolysates
(Sardina pilchardus and Boops boops) in cholesterol-fed rats”, Nutrition and Food Science,
Vol. 45 No. 3, pp. 448-466.
Bettzieche, A., Brandsch, C., Weiße, K., Hirche, F., Eder, K. and Stang, G.I. (2008), “Lupin protein
influences the expression of hepatic genes involved in fatty acid synthesis and triacylglycerol
hydrolysis of adult rats”, British Journal of Nutrition, Vol. 99 No. 05, pp. 952-962.
Bouchenak, M. and Lamri-Senhadji, M. (2013), “Nutritional quality of legumes, and their role in
cardiometabolic risk prevention: a review”, Journal of Medicinal Food, Vol. 16 No. 3, pp. 185-198.
Boye, J.I., Aksay, S., Roufik, S., Ribéreau, S., Mondor, M., Farnworth, E. and Rajamohamed, S.H. (2010),
“Comparison of the functional properties of pea, chickpea and lentil protein concentrates
processed using ultrafiltration and isoelectric precipitation techniques”, Food Research
International, Vol. 43 No. 2, pp. 537-546.
Bukhari, S.B., Bhanger, M.I. and Memon, S. (2008), “Antioxidative activity of extracts from fenugreek
seeds (Trigonella foenum-graecum)”, Pakistan Journal of Analytical and Environmental
Chemistry, Vol. 9, pp. 78-83.
Cho, S.J., Juillerat, M.A. and Lee, C.H. (2007), “Cholesterol lowering mechanism of soybean protein
hydrolysate”, Journal of Agricultural and Food Chemistry, Vol. 55 No. 26, pp. 10599-10604.
Antioxidant
properties in
rats
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
Christiane, K.F., Ellen, N. and Helene, L. (2009), “Allergenicity and antigenicity of fenugreek (Trigonella
foenum-graecum) proteins in foods”, Journal of Allergy and Clinical Immunology, Vol. 123 No. 1,
pp. 187-194.
Cicero, A.F.G., Fogacci, F. and Colletti, A. (2017), “Potential role of bioactive peptides in prevention and
treatment of chronic diseases: a narrative review”, British Journal of Pharmacology, Vol. 174
No. 11, pp. 1378-1394.
Council of European Communities (1986), “Council instructions about the protection of living animals
used in scientific investigations”, Official Journal of the European Communities (JO 86/609/
CEE), Vol. L358, pp. 1-18. Brussels.
Devrim, E., Ergüder, I.B., Ozbek, H. and Durak, I. (2008), “High-cholesterol diet increases xanthine
oxidase and decreases nitric oxide synthase activities in erythrocytes from rats”, Nutrition
Research, Vol. 28 No. 3, pp. 212-215.
Duka, A., Fotakis, P., Georgiadou, D., Kateifides, A., Tzavlaki, K., Von Eckardstein, L., Stratikos, E.,
Kardassis, D. and Zannis, V.I. (2013), “ApoA-IV promotes the biogenesis of apoA-IV-containing
HDL particles with the participation of ABCA1 and LCAT”, Journal of Lipid Research, Vol. 54
No. 1, pp. 107-115.
Eckerson, H.W., Wyte, C., La. and Du, B.N. (1983), “The human serum paraoxonase/arylesterase
polymorphism”,American Journal of Human Genetics, Vol. 35, pp. 1126-1138.
El Khoury, D. and Anderson, G.H. (2013), “Recent advances in dietary proteins and lipid metabolism”,
Current Opinion in Lipidology, Vol. 24 No. 3, pp. 207-213.
Elmnan, A., Balgees, A. and Mangara, J.L. (2012), “Effect of fenugreek (trigonella foenm greacum) seed
dietary levels on lipid profile and body weight gain of rats”, Pakistan Journal of Nutrition,
Vol. 11 No. 11, pp. 1004-1008.
Eyer, P., Worek, F., Kiderlen, D., Sinko, G., Stuglin, A., Simeon-Rudolf, V. and Reiner, E. (2003), “Molar
absorption coefficients for the reduced ellman reagent: reassessment”, Analytical Biochemistry,
Vol. 312 No. 2, pp. 224-227.
Fassini, P.G., Noda, R.W., Ferreira, E.S., Silva, M.A., Neves, V.A. and Demonte, A. (2011), “Soybean
glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic
rats”, Lipids in Health and Disease, Vol. 10, pp. 165-171.
Ferreira, E.S., Amaral, A.L.S., Demonte, A., Zanelli, C.F., Capraro, J., Duranti, M. and Neves, V.A. (2015),
“Hypocholesterolaemic effect of rat-administered oral doses of the isolated 7S globulins from
cowpeas and adzuki beans”, Journal of Nutritional Science, Vol. 4, pp. 1-9.
Ferrières, J., Bongard, V., Dallongeville, J., Arveiler, D., Cottel, D., Haas, B., Wagner, A., Amouyel, P. and
Ruidavets, J.B. (2009), “Trends in plasma lipids, lipoproteins and dyslipidaemias in French
adults, 1996-2007”,Archives of Cardiovascular Diseases, Vol. 102 No. 4, pp. 293-301.
Folch, J., Lees, M. and Sloane-Stanley, G.H. (1957), “A simple method for isolation and purification of
total lipids from animal tissues”, Journal of Biology and Chemistry, Vol. 226, pp. 497-509.
Garcia, M.C., Puchalska, P., Esteve, C. and Marina, M.L. (2013), “Vegetable foods: a cheap source of
proteins and peptides with antihypertensive, antioxidant, and other less occurrence
bioactivities”,Talanta, Vol. 106, pp. 328-349.
Guallar-Castillon, P., Gil-Montero, M., Leon-Muñoz, L.M., Graciani, A., Bayán-Bravo, A., Taboada, J.M.,
Banegas, J.R. and Rodríguez-Artalejo, F. (2012), “Magnitud y manejo de la hipercolesterolemia en
la poblacion adulta de España, 2008-2010, el estudio ENRICA”, Revista Española de Cardiología,
Vol. 65 No. 6, pp. 551-558.
Habib-Martin, Z., Hammad, H., Afifi, F., Zihlif, M., Al-Ameer, H., Saleh, M., Abaza, I. and Nassar, Z.
(2017), “In vitro and in vivo evaluation of the antiangiogenic activities of Trigonella foenum-
graecum extracts”,Asian Pacific Journal of Tropical Biomedicine, Vol. 7 No. 8, pp. 732-738.
Hafiane, A. and Genest, J. (2013), “HDL, atherosclerosis, and emerging therapies”, Cholesterol, available
at: http://dx.doi.org/10.1155/2013/891403
NFS
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
He, X., Chen, F., Mcgovern, M.M. and Schuchman, E.H. (2002), “A fluorescence based, high-throughput
sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of
sphingomyelin metabolism”,Analytical Biochemistry, Vol. 306 No. 1, pp. 115-123.
Hojjati, M.R. and Jiang, X.C. (2006), “Rapid, specific, and sensitive measurements of plasma sphingomyelin
and phosphatidylcholine”, Journal of Lipid Research, Vol. 47 No. 3, pp. 673-676.
Horwitz, W. (2000), Official Methods of Analysis of AOAC International: Food Composition, Additives,
Natural Contaminants, AOAC International, Gaithersburg, MD.
Hubácek, J.A., Bobková, D., Bohuslavová, R. and Poledne, R. (2008), “Differences in expression of
cholesterol 7a-hydroxylase between PHHC and wistar rats”, Folia Biologica, Vol. 54 No. 1,
pp. 18-23.
Institut National de Santé Publique (2007), “Enquête nationale santé: transition épidémiologique et
système de santé. Projet TAHINA”, Ministère de la Santé, de la Population et de la Réforme
Hospitaliaire, El Biar.
Kang, S. and Davis, R.A. (2000), “Cholesterol and hepatic lipoprotein assembly and secretion”,
Biochimica et Biophysica Acta, Vol. 1529 Nos 1/3, pp. 223-230.
Kapravelou, G., Martínez, R., Andrade, A.M., Sánchez, C., Chaves, C.L., Lopez-Jurado, M., Aranda, P.,
Cantarero, S., Arrebola, F., Fernández-Segura, E., Galisteo, M. and Porres, J.M. (2013), “Health
promoting effects of lupin (lupinus albus var. multolupa) protein hydrolyzate and insoluble fiber
in a diet-induced animal experimental model of hypercholesterolemia”, Food Research
International, Vol. 54 No. 2, pp. 1471-1481.
Khorshidian, N., Asli, M.Y., Arab, M., Mirzaie, A.A. and Mortazavian, A.M. (2016), “Fenugreek:
potential applications as a functional food and nutraceutical”, Nutrition and Food Sciences
Research, Vol. 3 No. 1, pp. 5-16.
Ktari, N., Belguith-Hadriche, O., Ben Amara, I., Ben Hadj, A., Turki, M., Makni-Ayedi, F., Boudaouara,
T., El Feki, A., Boualga, A., Ben Salah, R. and Nasri, M. (2015), “Cholesterol regulatory effects
and antioxidant activities of protein hydrolysates from zebra blenny (Salaria basilisca) in
cholesterol-fed rats”, Food and Function, Vol. 6 No. 7, pp. 2273-2282.
Lemes, A.C., Sala, L., Ores, J.C., Braga, A.R.C., Egea, M.B. and Fernandes, K.F. (2016), “A review of the
latest advances in encrypted bioactive peptides from protein-rich waste”, International Journal
of Molecular Sciences, Vol. 17 No. 6, pp. 950-973.
Leon-Espinosa, E.B., Sánchez-Chino, X., Garduño-Siciliano, L., Álvarez-González, R.I., Dávila-Ortiz, G.,
Madrigal-Bujaidar, E., Téllez-Medina, D.I. and Jiménez-Martínez, C. (2016), “Hypocholesterolemic
and anticarcinogenic effect of vicia faba protein hydrolyzates”, Nutrition and Cancer, Vol. 68
No. 5, pp. 856-864.
Lopez-Barrios, L., Gutiérrez-Uribe, J.A. and Serna-Saldívar, S.O. (2014), “Bioactive peptides and
hydrolysates from pulses and their potential use as functional ingredients”, Journal of Food
Science, Vol. 79 No. 3, pp. 273-283.
Madhava Naidu, M., Shyamala, B.N., Pura, N., J., Sulochanamma, G. and Srinivas, P. (2011), “Chemical
composition and antioxidant activity of the husk and endosperm of fenugreek seeds”, Food
Science and Technology, Vol. Vol. 44, pp. 451-456.
Meghwal, M. and Goswami, T.K. (2012), “A review on the functional properties, nutritional content,
medicinal utilization and potential application of fenugreek”, Journal of Food Processing
Technology, Vol. 3, pp. 181-190.
Möller, N.P., Scholz-Ahrens, K.E., Roos, N. and Schrezenmeir, J. (2008), “Bioactive peptides and
proteins from foods: indication for health effects”, European Journal of Nutrition, Vol. 47
No. 4, pp. 171-182.
Mowla, A., Alauddin, M., Rahman, M.A. and Ahmed, K. (2009), “Antihyperglycemic effect of trigonella
foenum-graecum (fenugreek) seed extract in alloxan-induced diabetic rats and its use in diabetes
mellitus: a brief qualitative phytochemical and acute toxicity test on the extract”, African
Journal of Traditional, Complementary and Alternative Medicines, Vol. 6 No. 3, pp. 255-261.
Antioxidant
properties in
rats
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
Nasri, M. (2017), “Protein hydrolysates and biopeptides: Production, biological activities, and
applications in foods and health benefits: a review”, in Toldrá, F. (Ed.), Advances in Food and
Nutrition Research, Academic Press, Cambridge, pp. 109-159.
Navab, M., Hama, S.Y., Hough, G.P., Subbanagounder, G., Reddy, S.T. and Fogelman, L.M.
(2001), “A cell-free assay for detecting HDL that is dysfunctional in preventing the
formation of or inactivating oxidized phospholipids”, Journal of Lipid Research, Vol. 42
No. 8, pp. 1308-1317.
Navarro, M.A., Carpintero, R., Acin, S., Arbones-Mainar, J.M., Calleja, L., Carnicer, R. and Surra, J.C.
(2005), “Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental
inflammation”, Cytokine, Vol. 31 No. 1, pp. 52-63.
Reddy, R.R.L. and Srinivasan, K. (2011), “Dietary fenugreek and onion attenuate cholesterol gallstone
formation in lithogenic diet-fed mice”, International Journal of Experimental Pathology, Vol. 92
No. 5, pp. 308-319.
Röhrl, C. and Stangl, H. (2013), “HDL endocytosis and resecretion”, Biochimica et Biophysica Acta,
Vol. 1831 No. 11, pp. 1626-1633.
Ruiz, J.C.R., Ancona, DB. and Campos, M.R.S. (2014), “Bioactive vegetable proteins and peptides in
lipid-lowering; nutraceutical potential”,Nutricion Hospitalaria, Vol. 29, pp. 776-784.
Sarmadi, B.H. and Ismail, A. (2010), “Antioxidative peptides from food proteins: a review”, Peptides,
Vol. 31 No. 10, pp. 1949-1956.
Sedlak, J. and Lindsay, R.H. (1968), “Estimation of total, protein-bound, and nonprotein sulfhydryl
groups in tissue with Ellman’s reagent”,Analytical Biochemistry, Vol. 25, pp. 192-205.
Shahidi, F., Janitha, P.K. and Wanasundara, P.D. (1992), “Phenolic antioxidants”, Critical Reviews in
Food Science and Nutrition, Vol. 32 No. 1, pp. 67-103.
Soufleros, E. and Bertrand, A. (1998), “Evaluation d’une méthode CLHP adaptée au dosage des acides
aminés du vin”,Vitis-Journal of Grapevine Research, Vol. 37, pp. 43-53.
Srinivasan, K. (2013), “Dietary spices as beneficial modulators of lipid profile in conditions of metabolic
disorders and diseases”, Food & Function, Vol. 4 No. 4, pp. 503-521.
Toth, P.P., Potter, D. and Ming, E.E. (2012), “Prevalence of lipid abnormalities in the United States: the
national health and nutrition examination survey 2003-2006”, Journal of Clinical Lipidology,
Vol. 6 No. 4, pp. 325-330.
Udenigwe, C.C. and Howard, A. (2013), “Meat proteome as source of functional biopeptides”, Food
Research International, Vol. 54 No. 1, pp. 1021-1032.
Udenigwe, C.C. and Rouvinen-Watt, K. (2015), “The role of food peptides in lipid metabolism during
dyslipidemia and associated health conditions”, International Journal of Molecular Sciences,
Vol. 16 No. 12, pp. 9303-9313.
Wang, Y.M., Zhang, B., Xue, Y., Li, Z.J., Wang, J.F., Xue, C.H. and Yanagita, T. (2010), “The mechanism
of dietary cholesterol effects on lipids metabolism in rats”, Lipids in Health and Disease, Vol. 9,
pp. 4-9.
Yahia, S., Benomar, S., Dehiba, F., Allaoui, A., Guillen, N., Rodriguez-Yoldi, M.J., Osada, J. and Boualga,
A. (2017), “Hypocholesterolemic and antioxidant efficiency of chickpea (cicer arietinum) protein
hydrolysates depend on its degree of hydrolysis in cholesterol-fed rat”, Nutrition and Food
Science, Vol. 47 No. 2, pp. 254-269.
Yang, S.C., Liu, S.M., Yang, H.Y., Lin, Y.H. and Chen, J.R. (2007), “Soybean protein hydrolysate
improves plasma and liver lipid profiles in rats fed high-cholesterol diet”, The Journal of the
American College of Nutrition, Vol. 26 No. 5, pp. 416-423.
Author affiliations
Amine Allaoui, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la Nature et de
la Vie, Université Oran1 Ahmed Ben Bella, Oran, Algeria
NFS
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
Cristina Barranquero, Departamento de Bioquímica y Biología Molecular y Celular, Health Research
Institute of Aragon, CIBERobn, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza,
Spain
Sanaa Yahia, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la Nature et de la
Vie, Université Oran1 Ahmed Ben Bella, Oran, Algeria
Luis Vicente Herrera-Marcos, Departamento de Bioquímica y Biología Molecular y Celular, Health
Research Institute of Aragon, CIBERobn, Facultad de Veterinaria, Universidad de Zaragoza,
Zaragoza, Spain
Souhila Benomar, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la Nature et
de la Vie, Université Oran1 Ahmed Ben Bella, Oran, Algeria
Mourad Jridi, Laboratoire de Génie Enzymatique et de Microbiologie – Ecole Nationale d’Ingénieurs de
Sfax, University of Sfax, Sfax, Tunisia
María Ángeles Navarro, Departamento de Bioquímica y Biología Molecular y Celular, Health Research
Institute of Aragon, CIBERobn, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza,
Spain
Maria Jesús Rodriguez-Yoldi, Departamento de Farmacología y Fisiología. Unidad de Fisiología, Health
Research Institute of Aragon, CIBERobn, Facultad de Veterinaria, Universidad de Zaragoza,
Zaragoza, Spain
Moncef Nasri, Laboratoire de Génie Enzymatique et de Microbiologie – Ecole Nationale d’Ingénieurs de
Sfax, University of Sfax, Sfax, Tunisia
Jesús Osada, Departamento de Bioquímica y Biología Molecular y Celular, Health Research Institute of
Aragon, CIBERobn, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza, Spain
Ahmed Boualga, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la Nature et
de la Vie, Université Oran1 Ahmed Ben Bella, Oran, Algeria
About the authors
Amine Allaoui , PhD Student, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences
de la Nature et de la Vie, Université Oran1 Ahmed Ben Bella.
Cristina Barranquero, PhD Student, Department of Biochemistry and Molecular and Cellular
Biology, University of Zaragoza (Spain).
Sanaa Yahia, PhD, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la
Nature et de la Vie, Université Oran1 Ahmed Ben Bella.
Luis V. Herrera-Marcos, PhD Student, Department of Biochemistry and Molecular and Cellular
Biology, University of Zaragoza (Spain).
Souhila Benomar, PhD, Laboratoire de Nutrition Clinique et Métabolique, Faculté de Sciences de la
Nature et de la Vie, Université Oran1 Ahmed Ben Bella.
Mourad Jridi : PhD Enzymatic Engineering, Department of Biological Engineering of the National
School of Engineers of Sfax.
María Ángeles Ferrando Navarro, Department of Biochemistry and Molecular and Cellular
Biology, University of Zaragoza (Spain).
Maria Jesús Rodriguez-Yoldi, PhD Sciences, Department of Physiology and Pharmacology.
University of Zaragoza (Spain). Member of Physiology Society.
Moncef Nasri, PhD Enzymatic Engineering-Microbiology, Department of Biological Engineering of
the National School of Engineers of Sfax.
Jesús Osada PhD in biochemistry and molecular biology Department of Biochemistry and
Molecular and Cellular Biology, University of Zaragoza (Spain).
Ahmed Boualga, PhD in physiology of nutrition, Laboratoire de Nutrition Clinique et Métabolique,
Faculté de Sciences de la Nature et de la Vie, Université Oran1 Ahmed Ben Bella. Ahmed Boualga is
the corresponding author and can be contacted at: boualga.ahmed@univ-oran.dz
Antioxidant
properties in
rats
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EW
 E
N
G
LA
N
D
 (A
US
) A
t 0
0:0
5 0
6 O
cto
be
r 2
01
8 (
PT
)
